SCHEDULE: Millennium Management Discloses 5.1% Stake in Tenax

Millennium Management LLC and Israel A. Englander have reported a 5.1% beneficial ownership stake in Tenax Therapeutics, Inc.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander filed a Schedule 13G indicating a collective beneficial ownership of 1,347,130 shares of Tenax Therapeutics, Inc. common stock.
• This holding represents 5.1% of the company's outstanding common stock.
• The filing confirms the acquisition of these shares as of May 18, 2026.
• The reporting persons certify that the shares were acquired for investment purposes and not to influence or change the control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive event, as it reflects institutional confidence in the company's equity, though it is a standard regulatory filing without specific operational news.

Positives

• Institutional validation from a major investment firm like Millennium Management.
• The acquisition of a 5.1% stake indicates significant interest from a sophisticated investor.

Negatives

• None identified; this is a standard regulatory disclosure of beneficial ownership.

Risks

• The filing notes that the securities are held by entities subject to investment discretion, which may be subject to market volatility.
• The investment is passive in nature, meaning the firm does not intend to influence corporate strategy.

Future Outlook

The reporting persons have stated that the shares were not acquired for the purpose of changing or influencing the control of the issuer, indicating a passive investment stance.

Management Comments

• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional filings of this nature are common in the biotech sector, where large hedge funds often take positions in small-cap companies ahead of clinical milestones or potential strategic shifts.

Comparison to Industry Standards

• The 5.1% threshold is the standard regulatory trigger for public disclosure under SEC Rule 13G.
• Millennium Management's activity is consistent with its historical strategy of maintaining diversified, passive positions in small-cap growth equities.

Stakeholder Impact

• Shareholders may view the entry of a major institutional investor as a positive signal for liquidity and market confidence.

Next Steps

• The reporting persons will be required to file amendments if there are material changes to their percentage of ownership.

Key Dates

Keywords

Tenax Therapeutics, Millennium Management, Schedule 13G, Beneficial Ownership, Institutional Investor, TENX